Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia

Neuropsychopharmacology

Volumn 30, Issue 10, 2005, Pages 1913-1922

  Ritsner, Michael ^a,b   Gibel, Anatoly ^a   Maayan, Rachel ^c   Ratner, Yael ^a   Ram, Edward ^c   Biadsy, Hassan ^a   Modai, Ilan ^a,b   Weizman, Abraham ^c  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cortisol; Dehydroepiandrosterone; Dehydroepiandrosterone sulfate; Neurosteroids; Prospective study; Responsivity to treatment; Schizophrenia

Indexed keywords

BENZODIAZEPINE; BIOLOGICAL MARKER; CLOTIAPINE; CLOZAPINE; FLUPENTIXOL DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; HYDROCORTISONE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PRASTERONE; RISPERIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; EMOTIONAL STRESS; FEMALE; HOSPITAL PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MALE; PATIENT CODING; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL MODEL;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DEHYDROEPIANDROSTERONE; DRUG RESISTANCE; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; SCHIZOPHRENIA; TIME FACTORS;

EID: 27144435117     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300747     Document Type: Article

References (52)

1. Akwa Y, Baulieu EE (2000). Dehydroepiandrosterone sulfate and dehydroepiandrosterone: neuroactive neurosteroids. Curr Opin Endocrinol Diabetes 7: 160-167.
2. Barbaccia ML, Affricano D, Purdy RH, Maciocco E, Spiga F, Biggio G (2001). Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology 25: 489-497.
3. Binello E, Gordon CM (2003). Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol 3: 635-641.
4. Boudarene M, Legros JJ (2002). Study of the stress response: role of anxiety, cortisol and DHEA-S. Encephale 28: 139-146.
5. Brophy MH, Rush AJ, Crowley G (1983). Cortisol, estradiol, and androgens in acutely ill paranoid schizophrenics. Biol Psychiatry 18: 583-590.
6. Cardounel A, Regelson W, Kalimi M (1999). Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action. Proc Soc Exp Biol Med 222: 145-149.
7. Carlstrom K, Brody S, Lunell N-O, Lagrelius A, Mollerstrom G, Pousette A et al (1988). Dehydroepiandrosterone sulphate and dehydroepiandrosterone in serum: differences related to age and sex. Maturitas 10: 297-306.
8. Ceskova E, Drybcak P, Hrobar P, Lorenc M, Hana, Prochazkova et al (2001). The changes of biological markers and treatment efficacy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25: 323-335.
9. Debonnel G, Bergeron R, de Montigny C (1996). Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. J Endocrinol 150(Suppl): S33-S42.
10. Erb JL, Kadane JB, Tourney G, Mickelsen R, Trader D, Szabo R et al (1981). Discrimination between schizophrenic and control subjects by means of plasma dehydroepiandrosterone measurements. J Clin Endocrinol Metab 52: 181-186.
11. First M, Spitzer RL, Gibbon M, Williams JBW (1995). SCID (DSM-IV) Structured Clinical Interview for Axis IDSM-IV Disorders - Patient Edition (SCID-I/P). Biometrics Research Department, New York State Psychiatric Institute: New York.
12. Goodyer IM, Herbert J, Altham PM (1988). Adrenal steroid secretion and major depression in 8- to 16-year-olds. III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med 28: 265-273.
13. Guazzo EP, Kirkpatrick PJ, Goodyer IM, Shiers HM, Herbert J (1996). Cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age. J Clin Endocrinol Metab 81: 3951-3960.
14. Guy W (1976). ECDU Assessment Manual for Psychopharmacology. US Department of Health and Human Services: Rockville, MD.
15. Harris DS, Wolkowitz OM, Reus VI (2001). Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J Biol Psychiatry 2: 99-102.
16. Hintze JL (1998). NCSS 6.0. Statistical System for Windows. User's Guide. Number Cruncher Statistical Systems: Kaysville: Utah.
17. Johnson MD, Bebb RA, Sirrs SM (2002). Uses of DHEA in aging and other disease states. Ageing Res Rev 1: 29-41.
18. Kaneda Y, Fujii A, Ohmori T (2002). The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 26: 935-938.
19. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-267.
20. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J (1998). Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 95: 1852-1857.
21. Kimonides VG, Spillantini MG, Sofroniew MV, Fawcett JW, Herbert J (1999). Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 89: 429-436.
22. Kroboth PD, Amico JA, Stone RA, Folan M, Frye RF, Kroboth FJ et al (2003). Influence of DHEA administration on 24-hour cortisol concentrations. J Clin Psychopharmacol 23: 96-99.
23. Kroboth PD, Salek FS, Stone RA, Bertz RJ, Kroboth 3rd FJ (1999). Alprazolam increases dehydroepiandrosterone concentrations. Clin Psychopharmacol 19: 114-124.
24. Lee JH, Woo JI, Meltzer HY (2001). Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry Res 103: 157-166.
25. Leowattana W (2004). DHEAS as a new diagnostic tool. Clin Chim Acta 341: 1-15.
26. Lhullier FL, Nicolaidis R, Riera NG, Cipriani F, Junqueira D, Dahm KC et al (2004). Dehydroepiandrosterone increases synaptosomal glutamate release and improves the performance in inhibitory avoidance task. Pharmacol Biochem Behav 77: 601-606.
27. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L et al (2003). Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28: 995-1003. Epub 2003 Mar 26.
28. Majewska MD (1992). Neurosteroids: endogenous bimodal modulators of the GABAa receptor. Mechanisms of action and physiological significance. Prog Neurobiol 38: 379-395.
29. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL (2003). Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 28: 1-13.
30. Meltzer HY, Lee MA, Jayathilake K (2001). The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology 24: 278-290.
31. Morley JE, Kaiser F, Raum WJ, Perry III HM, Flood JF, Jensen J et al (1997). Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 94: 7537-7542.
32. Muck-Seler D, Pivac N, Jakovljevic M, Brzovic Z (1999). Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiatry 45: 1433-1439.
33. Nafziger AN, Bowlin SJ, Jenkins PL, Pearson TA (1998). Longitudinal changes in dehydroepiandrosterone concentrations in men and women. J Lab Clin Med 131: 316-323.
34. Nechmad A, Maayan R, Ramadan E, Morad O, Poyurovsky M, Weizman A (2003). Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. Eur Neuropsychopharmacol 13: 29-31.
35. Oades RD, Schepker R (1994). Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 19: 373-385.
36. Oertel GW, Benes P, Schirazi M, Holzmann H, Hoffmann G (1974). Interaction between dehydroepiandrosterone, cyclic adenosine-3′, 5′-monophosphate and glucose-6-phosphate-dehydrogenase in normal and diseased subjects. Experientia 30: 872-873.
37. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H (1992). Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75: 1002-1004.
38. Pisua MG, Serra M (2004). Neurosteroids and neuroactive drugs in mental disorders. Life Sci 74: 3181-3197.
39. Ritsner M, Maayan R, Gibel A, Strous RD, Modai I et al (2004). Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol 14: 267-273.
40. Ritsner M, Modai I, Ponizovsky A (2002). Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory. Compr Psychiatry 43: 229-234.
41. Ritsner M, Rabinowitz J, Slyuzberg M (1995). The Talbieh Brief Distress Inventory: a brief instrument to measure psychological distress among immigrants. Compr Psychiatry 36: 1-7.
42. Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T (2002). Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophr Res 58: 69-74.
43. Stoffel-Wagner B (2001). Neurosteroid metabolism in the human brain. Eur J Endocrinol 145: 669-679.
44. Strous RD, Maayan R, Lapidus R, Goredetsky L, Zeldich E, Kotler M et al (2004). Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone- sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res 71: 427-434.
45. Tourney G, Erb JL (1979). Temporal variations in androgens and stress hormones in control and schizophrenic subjects. Biol Psychiatry 14: 395-404.
46. Tourney G, Hatfield L (1972). Plasma androgens in male schizophrenics. Arch Gen Psychiatry 27: 753-755.
47. van Broekhoven F, Verkes RJ (2003). Neurosteroids in depression: a review. Psychopharmacology (Berl) 165: 97-110.
48. Walder DJ, Walker EF, Lewine RJ (2000). Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry 48: 1121-1132.
49. Wen S, Dong K, Onolfo JP, Vincens M (2001). Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. Eur J Pharmacol 430: 373-374.
50. White L, Harvey PD, Opler L, Lindenmayer JP (1997). Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. The PANSS Study Group. Psychopathology 30: 263-274.
51. WHO Collaborating Centre for Drug Statistics Methodology (2000). Guidelines for ATC Classification and DDD Assignment, 3rd edn. WHO Collaborating Centre for Drug Statistics Methodology: Oslo.
52. Wolf OT, Kirschbaum C (1999). Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Rev 30: 264-288.